menu
search
date_range
expand_more
1 Year
login
Sign In
home
Home
explore
Dashboard
bookmark_border
Bookmarks
show_chart
Portfolios
search
Explorer
arrow_drop_down
Funds
Equities
library_books
Library
rss_feed
Insights
link
Pinindices
smartphone
Mobile
arrow_drop_down
App Store
Android
Dashboard
chevron_right
Gene Editing
Next 60 MidCap Biotech Firms
With market capitalizations between $2bn and $10bn, the performance of the midcap biotech selection has gained momentum
trending_up
118.3%
list
61
Cell Therapies - Gene Editing
Investing in clinical trial firms, a high stakes bet on breakthrough research
trending_up
47.0%
list
19
Biotechnology - Top 100 by Market Cap
Targeted access to a large selection of biotechnology and pharmaceutical stocks (large-, mid- and small-cap)
trending_up
102.4%
list
100
China Biotech - Rising Stars ?
Concentrating minds on breakthrough medication - Chinese biotech with a mission
trending_up
21.8%
list
11
article
2
Cancer, Rare Diseases & Cell Therapies
Research Breakthrough and Pricing Challenges
trending_up
54.4%
list
26
article
2
Biotechnology - Genetic Revolutions
Small- and Mid-Cap biotech firms at the forefront of DNA manipulations and gene therapies
trending_up
64.2%
list
42
Biotechnology Breakthroughs ETFs
Diversified selections or focused investment models in Biotech R&D
trending_up
62.0%
list
10
Technology - ARK Innovation, prophet or poster child
The technology fund has been frontrunning market trends on the way up and is riding high, once again
trending_up
24.7%
list
20
Biotech Movers - a January '23 Surprise
Reversal of the negative 2022 trend of biotech firms has been notable - the industry remains volatile but investments could be rewarding
trending_up
37.1%
list
17
30 Biotech LargeCap Firms
The biotech firms, with market capitalization exceeding $10 billion, are strong contributors to the industry's performance - Momentum is indicative of the sector's resilience
trending_up
62.5%
list
30
Healthcare - Collaboration in CRISPR Expertise
A focus on collaborations between giant healthcare companies and clinical trial and research firms - signaling high-value potential (and high-stake bets)
trending_up
41.5%
list
8
